A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis

Pharmacotherapy

Volumn 19, Issue 5, 1999, Pages 620-626

  Bosso, John A ^a,b   Bonapace, Charles R ^a   Flume, Patrick A ^b   White, Roger L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LUNG FUNCTION TEST; MALE; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS AERUGINOSA;

EID: 0032900378     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.8.620.31525     Document Type: Article

References (24)

1. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-88.
2. Legged JE, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989;159:281-92.
3. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831-47.
4. Gerber AU, Feller C, Brugger HP. Time course of the pharmacological response to beta-lactam antibiotic in vitro and in vivo. Eur J Clin Microbiol 1984;3:592-7.
5. Leggett JE, Eben S, Fantin B, Craig WA. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 1991;suppl 74:179-84.
6. David TJ, Devlin J. Continuous infusion of ceftazidime in cystic fibrosis. Lancet 1989;1:1454-5.
7. Kuzemko J, Crawford C. Continuous infusion of ceftazidime in cystic fibrosis. Lancet 1989;2:385.
8. Taussig LM, Kattwinkel J, Friedewald WT, di Sant Agnese PA. A new prognostic score and clinical evaluation system for cystic fibrosis. J Pediatr 1973;82:380-90.
9. Leeder JS, Spino M, Isles AF, Tesoro AM, Gold R, MacLeod SM. Ceftazidime disposition in acute and stable cystic fibrosis. Clin Pharmacol Ther 1984;36:355-62.
10. Turner A, Pedler SJ, Carswell F, Spencer GR, Speller DCE. Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis. J Antimicrob Chemother 1984;14:521-7.
11. Blumer JL, Stern RC, Klinger JD, et al. Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant Pseudomonas. Am J Med 1985;79(suppl 2A):37-46.
12. Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates derived from cystic fibrosis patients. Antimicrob Agents Chemother 1997;41:2053-6.
13. Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. Comparative bactericidal activity of ceftazidime against isolates of Pseudomonas aeruginosa as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method. Antimicrob Agents Chemother 1997;41:2527-32.
14. Facca B, Frame B, Triesenberg S. Population pharmacokinetics of ceftizoxime administered by continuous infusion in clinically ill adult patients. Antimicrob Agents Chemother 1998;42:1783-7.
15. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991;suppl 74:63-70.
16. Cars O, Craig WA. General discussion on antibiotic dosing. Scand J Infect Dis 1991;suppl 74:282-3.
17. Mordenti JJ, Quintiliani R, Nightingale CH. Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model. J Antimicrob Chemother 1985;15(suppl A):313-21.
18. Roosendaal R, Bakker-Woudenberg IAJM, van den Berg JC, Michel MF. Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J Infect Dis 1985;152:373-8.
19. Peterson LR, Gerding DN, Fasching CE. Effects of method of antibiotic administration on extravascular penetration: crossover study of cefazolin given by intermittent injection or constant infusion. J Antimicrob Chemother 1981;7:71-9.
20. Lagast H, Meunier-Carpentier F, Klastersky J. Treatment of gram-negative bacillary septicemia with cefoperazone. Eur J Clin Microbiol 1983;2:554-8.
21. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979;67:608-16.
22. Daenen S, de Vries-Hospers H. Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime. Lancet 1988;1:937.
23. Vinks AATMM, Touw DJ, Heijerman HGM, Danhof M, de Leede GPJ, Bakker W. Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther Drug Monit 1994;16:341-8.
24. Hitt CM, Nightingale CH, Quintiliani R, Nicolau DP. Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime. Am J Health-Syst Pharm 1997;54:1614-18.